6. Mai 2022 – The EMA published the risk management plan for AstraZeneca’s Covid-19 treatment Evusheld. Evusheld contains the two active substances tixagevimab and cilgavimab and is a medicine used to prevent Covid-19 in adults and adolescents from 12 years of age weighing at least 40 kilograms. For more information, see here.